SCHEMBL1723145

SCHEMBL1723145

CCC(=O)Nc1cnc(C)cn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.56
SMN1; SMN2 Q16637 4/20 0.46
TSHR P16473 3/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HSD17B10 Q99714 4/20 0.46
MAPT P10636 3/20 0.44
RAB9A P51151 3/20 0.44
NPC1 O15118 2/20 0.44
TP53 P04637 1/20 0.44
MAPK1 P28482 1/20 0.44
MEN1 O00255 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
LMNA P02545 2/20 0.43
ALDH1A1 P00352 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
HPGD P15428 1/20 0.41
ABL1 P00519 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
ADORA1 P30542 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1850645 0.86 MAPT (0.56) NOTUMSMN1; SMN2MAPTRAB9ANPC1
SCHEMBL2629365 0.85 NOTUM (0.56) NOTUMSMN1; SMN2MAPTRAB9ANPC1
SCHEMBL1037837 0.84 NOTUM (0.55) NOTUMSMN1; SMN2TSHRMAPTRAB9A
SCHEMBL21765886 0.83 PTK2 (0.49) SMN1; SMN2TSHRNPSR1HSD17B10MAPT
SCHEMBL1848793 0.82 L3MBTL1 (0.61) NOTUMSMN1; SMN2MAPTRAB9ANPC1
SCHEMBL2629367 0.81 NOTUM (0.52) NOTUMSMN1; SMN2MAPTRAB9ANPC1
SCHEMBL2629366 0.81 NOTUM (0.63) NOTUMSMN1; SMN2TSHRMAPTRAB9A
SCHEMBL321546 0.80 NOTUM (0.50) NOTUMSMN1; SMN2MAPTRAB9ANPC1
SCHEMBL2227323 0.79 PTK2 (0.52) NOTUMSMN1; SMN2MAPTRAB9ANPC1
SCHEMBL18896187 0.77 ADORA3 (0.48) NOTUMSMN1; SMN2TSHRNPSR1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011529955-A 2011-12-15 JP claimed
EP-2324028-A2 THERAPEUTIC AGENTS 414 AstraZeneca AB (SE) 2011-05-25 EP claimed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO claimed
WO-2023220247-A1 LRRK2 INHIBITORS INTERLINE THERAPEUTICS, INC. (US) 2023-11-16 WO disclosed
CN-102171213-A Pyrazolo [3, 4] pyrimidin-4-yl derivatives and their uses to treat diabetes and obesity ASTRAZENECA AB 2011-08-31 CN disclosed
EP-2344458-A1 HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS Pfizer Inc. (US) 2011-07-20 EP disclosed
EP-2324028-A2 THERAPEUTIC AGENTS 414 AstraZeneca AB (SE) 2011-05-25 EP disclosed
WO-2010029461-A1 HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS PFIZER INC. (US) 2010-03-18 WO disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO disclosed